Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for treating moderately to severely active ulcerative colitis:
- Risankizumab for treating moderately to severely active ulcerative colitis (2024) NICE technology appraisal guidance 998
- Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (2024) NICE technology appraisal guidance 956
- Mirikizumab for treating moderately to severely active ulcerative colitis (2023) NICE technology appraisal guidance 925
- Upadacitinib for treating moderately to severely active ulcerative colitis (2023) NICE technology appraisal guidance 856
- Ozanimod for treating moderately to severely active ulcerative colitis (2022) NICE technology appraisal guidance 828
- Filgotinib for treating moderately to severely active ulcerative colitis (2022) NICE technology appraisal guidance 792
- Ustekinumab for treating moderately to severely active ulcerative colitis (2020) NICE technology appraisal guidance 633
- Tofacitinib for moderately to severely active ulcerative colitis (2018) NICE technology appraisal guidance 547
- Vedolizumab for treating moderately to severely active ulcerative colitis (2015) NICE technology appraisal guidance 342
- Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (2015) NICE technology appraisal guidance 329
This page was last updated: